Accuray Hosts Regional AERO Users' Meeting

SUNNYVALE, Calif., April 22, 2016 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the Accuray Exchange in Radiation Oncology (AERO™) Users' Meeting was held April 10 – 11, 2016 at the Palace Hotel in San Francisco, California. The two day summit, coordinated in partnership with teams from several University of California campuses, brought together radiation oncologists, physicists, therapists and administrators from around the world to discuss best practices and the future of radiation oncology. Founded in 2011, AERO was created for CyberKnife^® System and TomoTherapy^® System users dedicated to advancing patient care through worldwide clinical and technical collaboration.

Further information on Accuray, the CyberKnife and TomoTherapy Systems is available at www.accuray.com.

"It was stated repeatedly that this Users' Meeting was to be considered 'our' meeting – our opportunity as clinicians who have invested in the CyberKnife and/or TomoTherapy technology to come together to learn more to help our patients. But it was much more. It was a trifecta gathering to, (1) find out what is on the industry roadmap for the future, (2) understand results of new clinical strategies and trials that push the barriers of technology at clinics around the world, and (3) meet and associate with new colleagues to form collaborations that will continue to improve patients' care, outcomes, and quality of life," said Stanley H. Benedict, Ph.D., professor & vice chair of Clinical Physics, Department of Radiation Oncology, University of California at Davis Comprehensive Cancer Center and a speaker at the meeting.

More than two dozen specialized breakout sessions provided meeting participants with the opportunity to engage in peer-to-peer conversation related to delivering improved patient outcomes with fewer side effects and enhanced quality of life, at a reduced cost. An "Originators and Innovators" session featured presentations on the history behind the CyberKnife and TomoTherapy Systems, and innovative approaches clinicians are taking these technologies today to elevate radiation oncology to the next level. Additional meeting highlights included:

• A special session focused on "A New Paradigm in Expediting Quality Care in Radiation Therapy"
• A discussion about "Healthcare Economics: Market Trends and Transformation"
• A keynote address on "The Future of Radiation Oncology"
• Sessions specially designed for Administrators

"The CyberKnife and TomoTherapy users in attendance represent a distinguished group of practitioners who are advancing the use of radiation therapy across all cancer types," said Joshua H. Levine, president and chief executive officer of Accuray. "The information sharing that happens at these meetings is focused on an important goal – improving patient outcomes. The insights we gain through interacting with clinicians at this meeting will influence our product roadmap and drive technical innovations toward that goal."

The AERO community mission is to provide a global forum for the clinical exchange of information between clinicians and physicists for the purpose of setting a new standard in patient care and safety across treatments in the fields of SRS/SBRT, IMRT and conventional radiation therapy. Membership to AERO is free and open to all users of the CyberKnife^® and TomoTherapy^® Systems. Accuray is pleased to sponsor the 2016 Accuray pre-ESTRO Planning Workshop for all AERO™ members, to be held at the Hotel AlegroItalia Golden Palace in Turin, Italy on Thursday, April 28, 2016, from 12:00pm to 5:45pm. To learn more, visit www.accurayexchange.com.  

About the CyberKnife M6™ Series and TomoTherapy H™ Series Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series System efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies, as well as its future product offerings. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
[email protected]

Danielle Sullivan
MSLGROUP
+1 (781) 684-0770
[email protected]

Logo - http://photos.prnewswire.com/prnh/20160108/320376LOGO

SOURCE Accuray Incorporated

Related Links

http://www.accuray.com